Core Viewpoint - Biohaven Ltd. has entered into a significant investment agreement with Oberland Capital Management for up to $600 million, aimed at supporting ongoing clinical trials and commercialization efforts for its product, troriluzole, targeting spinocerebellar ataxia (SCA) [1][2][3] Group 1: Investment Details - The agreement includes an initial funding of $250 million to be provided at closing on or before April 30, 2025 [1][6] - An additional $150 million is contingent upon FDA approval of troriluzole, with further funding of up to $200 million available for strategic acquisitions and related expenses [3][6] - The investment is structured as a Note Purchase Agreement (NPA) that is non-dilutive to existing shareholders [3][6] Group 2: Product and Market Potential - Troriluzole is a novel prodrug designed to modulate glutamate levels, which has potential applications in various diseases beyond SCA [5][8] - The investment will facilitate the advancement of Biohaven's pipeline, which includes five innovative platforms across immunology, neuroscience, and oncology [3][8] Group 3: Strategic Partnership - Oberland Capital expresses confidence in Biohaven's ability to address unmet needs in rare diseases and is committed to supporting the launch of troriluzole [3][9] - The partnership is expected to leverage Oberland's expertise in funding rare disease product launches, enhancing Biohaven's operational capabilities [3][9]

On Friday's news that Biohaven (BHVN -15.34%) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage biotech was one of the biggest decliners in its industry, exiting Friday with a share price decline of over 15%. This was during a session that was essentially bullish; the S&P 500 index closed 0.6% higher. Strategic withdrawalThat news came not from Biohaven itself, but from the European Medicines Agency (EMA, t ...

LOS ANGELES, April 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE: BHVN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Biohaven announced its financial results for Q4 and full year 2024 on March 3, 2025. ...

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 3, 2025 ...

Core Insights - Biohaven Ltd. will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, showcasing its innovative neuroscience pipeline across various development programs [1][2] Company Developments - The presentations include 3 oral and 10 poster presentations, focusing on potential first-in-class therapies for neurological disorders with high unmet needs [2] - Biohaven's pipeline includes Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation [1][6] Oral Presentations - BHV-8000, a selective TYK2/JAK1 inhibitor, shows efficacy in a Parkinson's disease mouse model [3] - BHV-2100, a first-in-class TRPM3 antagonist, demonstrates safety and tolerability for pain and migraine [3] - Novel bispecific degrader BHV-1310 achieves significant IgG reduction in preclinical models [3] Poster Presentations - A qualitative assessment of the epilepsy patient experience through social media [4] - BHV-2100's development for migraine treatment [5] - A modern design for a Phase 2/3 study evaluating BHV-7000 in idiopathic generalized epilepsy [5] Company Overview - Biohaven focuses on discovering and developing treatments in immunology, neuroscience, and oncology, leveraging its drug development experience and proprietary platforms [6]

Shares of early-stage biotech stocks, including Biohaven (BHVN -8.53%), Recursion Pharmaceuticals (RXRX -6.62%), and CRISPR Therapeutics (CRSP -3.22%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence .The stocks endured multiple headwinds during the month, especially Biohaven, which had one of its drug candidates deliver underwhelming results in a recent study. In addition, all money-losing biotechs sold off hard along with ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 3, 2025, Biohaven i ...

Exhibit 99.1 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results • Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025. • Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 totaled approximately $489 million. • Reported posi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 001-41477 Biohaven Ltd. (Exact Name of Registran ...

Core Insights - Biohaven Ltd. has reported significant success with its investigational drug BHV-1300, a potential first-in-class IgG1,2,4 selective degrader, which has shown rapid and deep reductions in total IgG levels, indicating its potential for treating autoimmune diseases [1][3][7] Group 1: BHV-1300 Efficacy and Mechanism - In a four-week Phase 1 study, subcutaneous administration of BHV-1300 at a dose of 1000 mg weekly achieved reductions in total IgG of up to 84%, with a median reduction of 80% [2][3] - The drug selectively targets IgG1,2,4 while sparing IgG3, which is crucial for maintaining immune defense against infections [3][5] - BHV-1300 demonstrated progressive reductions in IgG levels within hours of each dose, with sustained effects over the study period [3][4] Group 2: Safety and Tolerability - BHV-1300 has been reported as safe and well-tolerated, with no clinically significant increases in liver enzymes or bilirubin, and no serious adverse events noted during the study [4][6] - Most adverse events were mild and self-resolving, with no discontinuations due to the study drug [4][6] Group 3: Future Development Plans - Based on the promising results, Biohaven plans to initiate a Phase 2 study in Graves' disease in mid-2025, with additional studies in other autoimmune diseases to follow [3][6] - The company aims to customize treatment approaches based on the depth and speed of IgG lowering achievable with BHV-1300 [3][4] Group 4: Market Context and Unmet Needs - Graves' disease affects approximately 3 million individuals in the US and 80 million globally, highlighting a significant unmet need for effective treatments that do not lead to permanent hypothyroidism or other severe side effects [6][7] - Current treatments for Graves' disease have remained unchanged for 70 years, creating an opportunity for innovative therapies like BHV-1300 to disrupt the existing treatment paradigm [6][7]